STOCK TITAN

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Nuvectis Pharma (NASDAQ: NVCT) has announced two upcoming scientific presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain (October 23-25, 2024).

The first presentation by Asier Unciti-Broceta from the University of Edinburgh will showcase NXP900's synergy with ALK inhibitors in ALK resistant cell lines. This poster session is scheduled for October 24th, 2024.

The second presentation by Ben King, also from the University of Edinburgh, will focus on using a multi-omics approach to identify biomarkers responding to NXP900. This poster session will take place on October 25th, 2024.

Nuvectis Pharma (NASDAQ: NVCT) ha annunciato due presentazioni scientifiche imminenti per NXP900 al Simposio AACR-NCI-EORTC sui Target Molecolari e Terapie Tumorali che si terrà a Barcellona, Spagna (23-25 ottobre 2024).

La prima presentazione, a cura di Asier Unciti-Broceta dell'Università di Edimburgo, metterà in evidenza la sinergia tra NXP900 e gli inibitori ALK nelle linee cellulari resistenti ad ALK. Questa sessione di poster è programmata per il 24 ottobre 2024.

La seconda presentazione, a cura di Ben King, anch'egli dell'Università di Edimburgo, si concentrerà su un approccio multi-omico per identificare biomarcatori che rispondono a NXP900. Questa sessione di poster si svolgerà il 25 ottobre 2024.

Nuvectis Pharma (NASDAQ: NVCT) ha anunciado dos próximas presentaciones científicas para NXP900 en el Simposio AACR-NCI-EORTC sobre Objetivos Moleculares y Terapias contra el Cáncer que se llevará a cabo en Barcelona, España (23-25 de octubre de 2024).

La primera presentación a cargo de Asier Unciti-Broceta de la Universidad de Edimburgo mostrará la sinergia de NXP900 con los inhibidores de ALK en líneas celulares resistentes a ALK. Esta sesión de póster está programada para el 24 de octubre de 2024.

La segunda presentación a cargo de Ben King, también de la Universidad de Edimburgo, se centrará en el uso de un enfoque multi-ómica para identificar biomarcadores que responden a NXP900. Esta sesión de póster tendrá lugar el 25 de octubre de 2024.

Nuvectis Pharma (NASDAQ: NVCT)NXP900에 대한 두 가지 다가오는 과학 발표를 2024 AACR-NCI-EORTC 분자 표적 및 암 치료 심포지엄에서 스페인 바르셀로나에서 발표할 예정입니다 (2024년 10월 23-25일).

첫 번째 발표는 에든버러 대학의 Asier Unciti-Broceta가 진행하며, NXP900과 ALK 억제제의 시너지 효과를 ALK 저항성 세포주에서 시연할 것입니다. 이 포스터 세션은 2024년 10월 24일로 예정되어 있습니다.

두 번째 발표는 같은 대학의 Ben King이 진행하며, NXP900에 반응하는 바이오마커를 식별하기 위한 멀티오믹스 접근법에 초점을 맞출 것입니다. 이 포스터 세션은 2024년 10월 25일에 진행됩니다.

Nuvectis Pharma (NASDAQ: NVCT) a annoncé deux présentations scientifiques à venir pour NXP900 lors du Symposium AACR-NCI-EORTC sur les cibles moléculaires et les thérapies contre le cancer à Barcelone, Espagne (23-25 octobre 2024).

La première présentation de Asier Unciti-Broceta de l’Université d’Édimbourg mettra en avant la synergie de NXP900 avec les inhibiteurs ALK dans les lignées cellulaires résistantes à ALK. Cette session d'affiches est prévue pour le 24 octobre 2024.

La deuxième présentation de Ben King, également de l’Université d’Édimbourg, se concentrera sur l’utilisation d’une approche multi-omique pour identifier les biomarqueurs réagissant à NXP900. Cette session d'affiches aura lieu le 25 octobre 2024.

Nuvectis Pharma (NASDAQ: NVCT) hat zwei bevorstehende wissenschaftliche Präsentationen zu NXP900 beim AACR-NCI-EORTC Symposium zu Molekularen Zielen und Krebsbehandlungen in Barcelona, Spanien (23.-25. Oktober 2024), angekündigt.

Die erste Präsentation von Asier Unciti-Broceta von der University of Edinburgh wird die Synergie von NXP900 mit ALK-Inhibitoren in ALK-resistenten Zelllinien vorstellen. Diese Postersitzung ist für den 24. Oktober 2024 geplant.

Die zweite Präsentation von Ben King, ebenfalls von der University of Edinburgh, wird sich auf die Verwendung eines multi-omischen Ansatzes zur Identifizierung von Biomarkern konzentrieren, die auf NXP900 reagieren. Diese Postersitzung findet am 25. Oktober 2024 statt.

Positive
  • None.
Negative
  • None.

Fort Lee, NJ, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP900 at the 2024 AACR-NCI-EORTC on Molecular Targets and Cancer Therapeutics (October 23-25, 2024, Barcelona, Spain).

Titles and Presenters Presentation Details
Title
NXP900, a novel YES1/SRC kinase inhibitor in phase 1 dose escalation, demonstrates potent synergy with ALK inhibitors in ALK resistant cell lines

Presenter
Asier Unciti-Broceta
University of Edinburgh
Scottland, UK
Session Title
Combination Therapies

Session Type
Poster

Session Date / Time
October 24th, 2024
09:00 - 17:30 CET
Title
A multi-omics approach to identify biomarkers of response to the novel and selective SRC/YES1 inhibitor NXP900

Presenter
Ben King
University of Edinburgh
Scottland, UK
Session Title
Cancer Genomics

Session Type
Poster

Session Date / Time
October 25th, 2024
09:00 - 15:00 CET

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. The U.S. Food and Drug Administration granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designations for the treatment of cholangiocarcinoma and ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study

Forward Looking Statements

Certain statements in this presentation constitute “forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nuvectis Pharma, Inc.'s current expectations, estimates, and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions, and other factors that are difficult to predict and include statements regarding the potential benefits of the Orphan Drug Designation granted to NXP800, the preclinical and the Phase 1a data generated to date for NXP800 and the clinical expectations for the NXP800 Phase 1b study, including statements regarding NXP800's mechanism of action and its potential ability to become a therapeutic option for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma, cholangiocarcinoma, and potentially other cancer indications, and the timing for this study. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are subject to market and other conditions and described more fully in the section titled "Risk Factors" in our 2Q 2024 Form 10-Q and our other public filings with the Securities and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward looking statements contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
rbentsur@nuvectis.com

Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com



FAQ

What presentations will Nuvectis Pharma (NVCT) give at the 2024 AACR-NCI-EORTC Symposium?

Nuvectis will present two posters: one on NXP900's synergy with ALK inhibitors in resistant cell lines, and another on biomarker identification for NXP900 response using multi-omics approaches.

When and where will Nuvectis Pharma (NVCT) present their NXP900 research?

The presentations will take place at the 2024 AACR-NCI-EORTC Symposium in Barcelona, Spain, on October 24th and 25th, 2024.

Who are the presenters for Nuvectis Pharma's (NVCT) NXP900 research?

Asier Unciti-Broceta and Ben King from the University of Edinburgh will present the NXP900 research findings.

What is the focus of NXP900 research by Nuvectis Pharma (NVCT)?

NXP900 is a novel YES1/SRC kinase inhibitor in phase 1 dose escalation, being studied for its synergy with ALK inhibitors and biomarker response patterns.

Nuvectis Pharma, Inc.

NASDAQ:NVCT

NVCT Rankings

NVCT Latest News

NVCT Stock Data

130.76M
18.65M
53.26%
11.75%
5.61%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FORT LEE